European Archives - Page 329 of 1007 - European Medical Journal

Inspiring innovation and the future of digital therapeutics

Helena and Jade introduce a discussion on the future of digital therapeutics with Eugene Borukhovich, Co-Founder and COO, YourCoach.Health.

Prosigna on demand webinars

Interactive webinar designed for doctors treating breast cancer interested in advancing personalized treatment through molecular gene expression testing.

The Emerging Role of Homologous Recombination Deficiency Testing and the Progress of PARP Inhibitors in Advanced Ovarian Cancer: Interviews with Three Key Opinion Leaders

Ovarian cancer is the most lethal gynaecologic malignancy worldwide because of its vague presentation, insidious nature, recurrence, and drug resistance.

EMJ Oncology 10 [Supplement 10] 2022

In this article, EMJ conducted interviews with three experts in the field of ovarian cancer, Ram Ganapathi, Department of Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic, Ohio, USA; Mansoor Raza Mirza, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark; and Rowan Miller, University College London Hospitals NHS Foundation Trust, UK.

Good Versus Bad: A Medical Discussion

Jonathan and William Barrett talk about the vilification of fats and how social media can be used as a way of altering HCPs when new research is available.

Daiichi Sankyo's Mary Pinder-Schenck on oncology innovation

Daiichi Sankyo’s Mary Pinder-Schenck speaks about the evolution she has witnessed in oncology throughout her career and what she predicts for the future of the field.

The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance

The over-production of TNF-α can lead to chronic inflammation and organ damage in immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), axial spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Anti-TNF therapy is generally considered to be an effective, well-tolerated treatment option for the management of chronic inflammation in these conditions.

From Clinical Trial to Real-World Evidence: Everyday Practice with METex14 Inhibitors in NSCLC

This recent hybrid satellite symposium, presented at the European Society for Medical Oncology (ESMO) 2022 Congress, addressed the current clinical practice for the management of patients with METexon14 (METex14) non-small cell lung cancer (NSCLC).

EMJ Gastroenterology 11 [Supplement 7]

This mini case study review article is the third in a series exploring tumour necrosis factor (TNF) inhibitors in the treatment of immune-mediated disease. This article explores anti-TNF therapies, which are generally considered to be an effective, well-tolerated treatment option for the management of chronic conditions related to the overproduction of TNF-α.

EMJ Diabetes 10.1 2022

The latest issue of EMJ Diabetes is now out and features an independent review of the European Association for the Study of Diabetes (EASD) Annual Meeting 2022.